Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

171 results about "Chimeric antibody" patented technology

Chimeric Antibodies. A chimeric antibody is a hybrid substance combining antibodies and parts of antibodies with the potential to track down and illuminate remote and microscopic tumors. It is less easily rejected by the body's immune system than the ordinary monoclonal antibody.

Antibody capable of binding to thymic stromal lymphopoietin and use thereof

Disclosed are an antibody capable of binding to thymic stromal lymphopoietin and the use thereof. Disclosed are an anti-TSLP antibody, comprising a murine antibody, chimeric antibody and humanized antibody of the light chain and heavy chain variable regions of the anti-TSLP antibody and antigen-binding fragments thereof, or a pharmaceutically acceptable salt or solvent compound thereof, and the use thereof as a medicament for treating asthma, especially the use thereof in the preparation of a drug for treating TSLP-positive diseases or conditions.
Owner:JIANGSU HENGRUI MEDICINE CO LTD +1

RO52 targeting antibody or antigen binding fragments thereof for use in treating cancer

Provided herein are methods of treating a cancer in a subject, wherein the cancer expresses a Ro52 antigen, comprising administering an anti-Ro52 binding agent to the subject, thereby treating the cancer in the subject. In some embodiments, the Ro52 antigen is expressed on a cancer cell surface. In some embodiments, the anti-Ro52 binding agent comprises a Fab, Fab', F(ab')2, Fahl-SH, Fv, diabody, linear antibody or single-chain variable fragment (scFv). In some embodiments, the anti-Ro52 binding agent is a humanized or chimeric antibody. In some embodiments, the anti-Ro52 binding agent is conjugated to a therapeutic agent.
Owner:JOHNS HOPKINS UNIVERSITY

Antibodies comprising chimeric constant domains

Antibodies, antigen-binding proteins and Fc-fusion proteins that comprise recombinant polypeptides containing a chimeric heavy chain constant region sequence are provided that bind to certain Fc receptors however have reduced effector functions. Methods of making constructs for expression of such chimeric Fc-containing antibodies, antigen-binding proteins and Fc-fusion proteins in cell systems, and methods of producing and isolating the chimeric Fc-containing proteins are provided.
Owner:REGENERON PHARMACEUTICALS INC

Anti-Claudin 18.2 antibody and application thereof

The present disclosure relates to an anti-Claudin 18.2 antibody and an application thereof. Specifically, the present invention relates to an anti-Claudin 18.2 antibody; a mouse-derived antibody, chimeric antibody, humanized antibody and antigen-binding fragment thereof which contain a CDR of the anti-Claudin 18.2 antibody, and a use thereof as a medicine. In particular, the present disclosure relates to a use of the anti-Claudin 18.2 antibody in the preparation of a drug for treating Claudin 18.2 positive diseases or disorders.
Owner:JIANGSU HENGRUI MEDICINE CO LTD +1

Anti-parvovirus canine-mouse chimeric antibody

The invention discloses an anti-parvovirus canine-mouse chimeric antibody, and belongs to the field of gene engineering, the chimeric antibody comprises a heavy chain variable region, a light chain variable region, a heavy chain constant region and a light chain constant region, the heavy chain variable region and the light chain variable region are mouse-derived fragments, and the heavy chain constant region and the light chain constant region are canine-derived fragments; the amino acid sequence of the heavy chain variable region is as shown in SEQ ID No.2, and the amino acid sequence of the light chain variable region is as shown in SEQ ID No.4. The canine-mouse chimeric antibody has broad-spectrum high neutralization activity on various subtypes of CPV in vitro, the immunological rejection of a mouse antibody in a canine body is reduced, and the canine infected by CPV-2c can be effectively treated by using the canine-mouse chimeric antibody.
Owner:HUAZHONG AGRI UNIV

Human-mouse chimeric monoclonal antibody of anti-human Hu protein and application of human-mouse chimeric monoclonal antibody

The invention provides an anti-human Hu protein human-mouse chimeric monoclonal antibody and application thereof, and belongs to the technical field of immunodetection. According to the anti-human Hu protein human-mouse chimeric monoclonal antibody provided by the invention, variable regions of a heavy chain and a light chain come from a mouse, the parent activity is reserved to the maximum extent, a constant region comes from a human source, and due to introduction of the human antibody constant region, the immunogenicity is greatly reduced, the occurrence probability of human anti-mouse antibody reaction is reduced, and the specificity of the antibody is improved. The human-mouse chimeric monoclonal antibody disclosed by the invention not only has antigen binding specificity, but also greatly reduces the heterology of the mouse monoclonal antibody. The chimeric antibody can recognize Hu protein, has biological activity, can be used for Hu antigen detection and other scientific researches, and has very good application value and very important scientific research guiding significance.
Owner:SHAANXI MYBIOTECH CO LTD

Anti-PM-Scl monoclonal antibody and application thereof

The invention relates to the technical field of biology, in particular to an anti-PM-Scl monoclonal antibody and application thereof. According to the invention, a PM-Scl recombinant protein is used as an antigen, and a phage display technology is used for screening to obtain the monoclonal antibody of the human PM-Scl. The monoclonal antibody is used as a raw material of a PM-Scl-IgG detection reagent quality control product, is good in universality and stability, can replace a clinical positive sample and be used as a quality control product of a third-party detection laboratory, saves the detection cost, is a human source, is closer to a natural sample in property compared with a human-mouse chimeric antibody, and has a good application prospect. Some matrix effect problems can be avoided.
Owner:ZHENGZHOU IMMUNO BIOTECH

Pig-mouse chimeric antibody for resisting porcine delta coronavirus and application of pig-mouse chimeric antibody

ActiveCN119080921AReduce heterologous reactionsImprove neutralizing treatment effectSsRNA viruses positive-senseImmunoglobulins against virusesHeterologousHeavy chain
The invention discloses a porcine-mouse chimeric antibody for resisting porcine delta coronavirus and application of the porcine-mouse chimeric antibody. The porcine-mouse chimeric antibody for resisting the porcine delta coronavirus is composed of a porcine heavy chain constant region, a porcine light chain constant region, a mouse heavy chain variable region and a mouse light chain variable region. The pig-mouse chimeric antibody disclosed by the invention can effectively reduce heterologous reaction of the antibody in a pig body, avoids the half-life period of the antibody from being shortened, the actual curative effect from being reduced and serious adverse reaction possibly caused by immune side reaction, improves the neutralizing treatment effect of the antibody, provides a practical gene engineering antibody for preventing and treating PDCoV, and has a wide application prospect. The important clinical application value is realized.
Owner:SICHUAN AGRI UNIV

Anti-CD155 antibody and use thereof

Provided in the present invention are an anti-CD155 antibody and the use thereof. Moreover, an obtained anti-CD155 chimeric antibody, a humanized anti-CD155 antibody, and a humanized affinity-matured anti-CD155 antibody can only specifically target and bind to a CD155 receptor and block the binding of CD155 to receptors TIGIT, CD96, and CD226 thereof, but also have the characteristic of not inducing the apoptosis of CD155 cells.
Owner:HEFEI TG IMMUNOPHARMA CO LTD

Torque converter

The application discloses TORCH antibody complex quality control and a preparation method thereof. The TORCH antibody complex quality control comprises TORCH IgM human-mouse chimeric antibodies selected from Toxoplasma gondii IgM chimeric antibodies, rubella virus IgM chimeric antibodies, cytomegalovirus IgM chimeric antibodies, herpes simplex virus type 1 IgM chimeric antibodies and herpes simplex virus type 2 IgM chimeric antibodies. The complex quality control is complete in form, good in stability, lower in cost, high in project complex degree and suitable for Abbott, Antu, Roche and Yaguilong chemiluminescence platforms, and better meets market demand.
Owner:SHENZHEN ZHAOLAN BIOTECHNOLOGY CO LTD

CD24 antibody, antigen-binding fragment thereof and use thereof

PCT designated stageWO2026149443A1AntigenAntiendomysial antibodies
Disclosed are a CD24 antibody or an antigen-binding fragment thereof and the medical use thereof. Further, disclosed are a chimeric antibody comprising CDRs of the CD24 antibody, a humanized antibody, a pharmaceutical composition comprising the CD24 antibody or the antigen-binding fragment thereof, and the use thereof as an anticancer drug.
Owner:HANGZHOU BIO SINCERITY PHARMA TECH CO LTD

Screening and application of targeted CLL1 fully humanized single-chain antibody

The invention belongs to the technical field of cellular immune engineering, and particularly relates to a full-human-derived polypeptide for recognizing CLL-1 and application of the full-human-derived polypeptide. The polypeptide provided by the invention specifically recognizes CLL-1 and has good affinity performance, and the polypeptide specifically targeting CLL-1 provided by the invention can mark CLL-1 positive cells, can be combined with a CLL-1 antigen and the CLL-1 positive cells, and can be used as a detection reagent of CLL-1 molecules and an in-vivo tracing marking reagent. The polypeptide specifically targeting CLL-1 provided by the invention can also be used in an extracellular antigen recognition region of a chimeric antigen receptor, is used in an immune cell treatment drug targeting CLL-1, and is used for killing malignant tumors expressing CLL-1. The polypeptide for specifically recognizing the CLL-1 is a natural full-humanized antibody source, compared with a mouse antibody, a chimeric antibody and a humanized antibody, the immunogenicity of the polypeptide is greatly reduced, and the safety can be guaranteed to the maximum extent in clinical application.
Owner:CHONGQING PRECISION BIOTECH CO LTD +1

Genetically modified mouse for preparing antibody and preparation method thereof

Genetically modified mice whose immunoglobulin loci are engineered to be inserted into gene segments of human immunoglobulin variable regions are disclosed, the mice being capable of normal reproduction and producing human-mouse chimeric antibodies comprising a human variable region and a mouse constant region. The invention also provides a method for preparing the genetically modified mouse and application of the mouse.
Owner:CYAGEN BIOSCIENCES (SUZHOU) INC

Anti-human OX40 inhibitory antibody or antigen binding fragment thereof, preparation method and application

The invention discloses an anti-human OX40 inhibitory antibody or an antigen binding fragment thereof, a preparation method and application, and belongs to the technical field of biological immunity. The EC50 of the human-mouse chimeric antibody Y07-L2 and the EC50 of the combination of the humanized antibody Y07-C2 and the human OX40, which are prepared by the invention, are close to those of a targeted antibody drug KHK-4083 for inhibiting the OX40. A heavy chain variable region of the human-mouse chimeric antibody Y07-L2 is as shown in SEQ ID NO.14, and a light chain variable region of the human-mouse chimeric antibody Y07-L2 is as shown in SEQ ID NO.15; the heavy chain variable region of the humanized antibody Y07-C2 is as shown in SEQ ID NO.20, and the light chain variable region of the humanized antibody Y07-C2 is as shown in SEQ ID NO.21; the CDR region of the humanized antibody Y07-C2 is mutated, and the mutant antibodies Y07-C2MH4 and Y07-C2MH4L3 are obviously superior to other antibodies.
Owner:NANJING UMAB-RUICARE BIOTECH CO LTD

Genetically modified mouse for antibody preparation and preparation method therefor

Disclosed is a genetically modified mouse having an immunoglobulin heavy chain locus engineered to insert a gene segment of a human immunoglobulin heavy chain variable region. The mouse is able to reproduce normally and produce a human-mouse chimeric antibody comprising a human heavy chain variable region and a mouse constant region. Also provided is a method for preparing the genetically modified mouse and use of the mouse.
Owner:CYAGEN BIOSCIENCES (SUZHOU) INC

Monoclonal antibody for recognizing NMI protein and application thereof

The invention relates to the technical field of monoclonal antibodies, and discloses a monoclonal antibody for recognizing NMI protein and application of the monoclonal antibody. The monoclonal antibody or the antigen binding fragment thereof comprises a heavy chain variable region and a light chain variable region, the amino acid sequence of the heavy chain variable region is as shown in SEQ ID NO.4, and the amino acid sequence of the light chain variable region is as shown in SEQ ID NO.9. The monoclonal antibody for recognizing the NMI protein and the chimeric antibody of the monoclonal antibody have an excellent specific recognition effect on the hNMI protein and the mNMI protein, and can be used for researching biological functions.
Owner:SUN YAT SEN UNIV

Screening and application of targeted CD5 fully humanized single-chain antibody

The invention belongs to the technical field of cellular immune engineering, and particularly relates to a full-human-derived polypeptide for recognizing CD5 and application of the full-human-derived polypeptide. The polypeptide specifically recognizes CD5 and is good in affinity performance, and the polypeptide specifically targeting CD5 can mark CD5 positive cells, can be combined with CD5 antigens and the CD5 positive cells and can serve as a detection reagent of CD5 molecules and an in-vivo tracing marking reagent. The polypeptide specifically targeting CD5 provided by the invention can also be used in an extracellular antigen recognition region of a chimeric antigen receptor, is used in an immune cell treatment drug targeting CD5, and is used for killing malignant tumors expressing CD5. The polypeptide capable of specifically recognizing CD5 is a natural full-humanized antibody source, compared with a mouse antibody, a chimeric antibody and a humanized antibody, the immunogenicity of the polypeptide is greatly reduced, and the safety can be guaranteed to the maximum extent in clinical application.
Owner:CHONGQING PRECISION BIOTECH CO LTD +1

Antigen binding protein targeting CD26 and drug application thereof

Relates to antigen binding proteins combined with human CD26 and application of the antigen binding proteins in preparation of drugs for treating tumors with high CD26 expression. The invention for the first time discloses a CD26 antigen binding protein which recognizes the same CD26 fragment or competes with antigen binding proteins comprising HCDR1 as shown in SEQ ID NO: 1, HCDR2 as shown in SEQ ID NO: 2, HCDR3 as shown in SEQ ID NO: 3, LCDR2 comprising LCDR1 as shown in SEQ ID NO: 4 and consisting of Arg Met Ser, and LCDR3 as shown in SEQ ID NO: 5. Compared with other mouse antibodies and corresponding chimeric antibodies or humanized antibodies, the CD26 antigen binding protein combined with amino acid residues in the amino acid sequence shown as SEQ ID NO: 59 or SEQ ID NO: 64 of CD26 shows better antigen affinity and good safety and effectiveness. And compared with the existing first-line treatment scheme (such as BAVENCIO for treating kidney cancer) of related tumors, the compound also shows more prominent effectiveness and safety.
Owner:ZONHON BIOPHARMA INST

Genetically modified mouse for preparing antibody and preparation method therefor

Disclosed in the present invention is a genetically modified mouse in which the immunoglobulin locus is engineered to be inserted with a gene segment of a human immunoglobulin variable region. The mouse is capable of reproducing normally and producing a human-mouse chimeric antibody, wherein the human-mouse chimeric antibody contains a human variable region and a mouse constant region. Further provided in the present invention is a method for preparing the genetically modified mouse and the use of the mouse.
Owner:CYAGEN BIOSCIENCES (SUZHOU) INC

Anti-b7h3 antibodies and application thereof

The present invention provides anti-B7H3 antibodies and their application thereof A group of murine anti-B7H3 monoclonal antibodies are prepared by hybridoma technology, using recombinant B7H3 protein as immunogen. Human-murine chimeric antibodies generated from the aforementioned murine anti-B7H3 hybridomas are capable of specifically binding to recombinant B7H3 protein and membrane-bound B7H3 on tumor cell lines. The derived B7H3 scFv-CD3ε-engineered T cells exhibit a significant cytotoxic effect on B7H3-positive tumor cell lines. Therefore, the anti-B7H3 antibodies and B7H3 scFv-CD3ε-engineered T cells have great application prospects in treating or ameliorating B7H3-associated diseases.
Owner:SCG CELL THERAPY PTE LTD

Monoclonal antibody specifically binding to EsxB and therapeutic reagent thereof

The invention relates to the technical field of biomedicine, in particular to a monoclonal antibody specifically combined with EsxB and a therapeutic reagent. The monoclonal antibody comprises a light chain variable region and a heavy chain variable region, the light chain variable region comprises three complementary determining regions VLCDR1, VLCDR2 and VLCDR3, the heavy chain variable region comprises three complementary determining regions VHCDR1, VHCDR2 and VHCDR3, the light chain variable region is an amino acid sequence which is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical with SEQ.ID.NO.1, and the heavy chain variable region is an amino acid sequence which is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical with SEQ.ID.NO.2; the therapeutic reagent comprises a monoclonal antibody, a single-chain antibody, a human-mouse chimeric antibody or a humanized antibody; the monoclonal antibody with high specificity, high neutralization activity and high protection force for EsxB provided by the invention has the characteristic of mediating complement-dependent cytotoxic effect, has excellent in-vivo antibacterial activity, and can support the construction of an anti-EsxB chimeric or humanized genetic engineering antibody with neutralization activity.
Owner:XIJING UNIV

Anti-BCMA antibody, antigen-binding fragment thereof and medical use thereof

Provided are an anti-BCMA antibody, an antigen-binding fragment thereof, and a medical use thereof. Further provided are a chimeric antibody and a humanized antibody containing a CDR region of the anti-BCMA antibody, a pharmaceutical composition containing the anti-BCMA antibody or the antigen-binding fragment thereof, and the use of same as an anti-cancer drug and for treating autoimmune diseases. Particularly, provided are a humanized anti-BCMA antibody, and the use of same in the preparation of a drug for treating BCMA-mediated diseases or conditions and the use of same in disease detection and diagnosis.
Owner:JIANGSU HANSOH PHARMA CO LTD +1

Antibody capable of binding to thymic stromal lymphopoietin and use thereof

PendingAU2020286889B2AntigenDisease
Disclosed are an antibody capable of binding to thymic stromal lymphopoietin and the use thereof. Disclosed are an anti-TSLP antibody, comprising a murine antibody, chimeric antibody and humanized antibody of the light chain and heavy chain variable regions of the anti-TSLP antibody and antigen-binding fragments thereof, or a pharmaceutically acceptable salt or solvent compound thereof, and the use thereof as a drug for treating asthma, especially the use thereof in the preparation of a drug for treating TSLP-positive diseases or conditions.
Owner:JIANGSU HENGRUI MEDICINE CO LTD +1

Anti-SIGLEC-5 antibodies and methods of use thereof

The present disclosure generally relates to compositions comprising antibodies, such as monoclonal antibodies, chimeric antibodies, humanized antibodies, antibody fragments, etc., that specifically bind to Siglec-5 proteins, such as human Siglec-5, and the use of such compositions in the prevention, risk reduction or treatment of individuals in need thereof.
Owner:艾利妥